Kevin Outterson, Esq., Professor of Law at Boston University and Executive Director of the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, will present for this month’s Levy CIMAR Science Meeting on “Innovation Solutions to AMR.”  CARB-X is a global partnership hosted at BU Law that is focused on supporting developers of promising new antibiotics, diagnostics, and vaccines that tackle the threat of untreatable bacterial infections. CARB-X has built the world’s largest and most innovative antibacterial pipeline, with $480 million in grant funding from three governments (US, UK, and Germany) and two foundations (Wellcome Trust and the Bill & Melinda Gates Foundation).

Professor Outterson also leads the Social Innovation on Drug Resistance program at Boston University. He is an associate fellow at the Royal Institute of International Affairs at Chatham House, London, where he works on global solutions to antibiotic resistance, and an appointed member of the Antimicrobial Resistance Working Group at the Centers for Disease Control. He also co-directs BU’s Health Law Program, currently ranked #5 in the country by US News and World Report. His interests include health law as well as intellectual property law. You can learn more about his work here.